此页面是自动翻译的，不保证翻译的准确性。请参阅英文版对于源文本。

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

2017年10月9日更新者：GlaxoSmithKline

A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD

This study is a 12-week, multicenter, randomized, double blind, parallel group, placebo-controlled study.

The purpose of this study is to replicate the therapeutic benefit of UMEC/VI 62.5/25 microgram (mcg) on health-related quality of life as reflected by St. George's Respiratory Questionnaire (SGRQ) scores and symptoms as reflected by rescue medication use observed in the 6 month placebo controlled study (DB2113373). Lung function will be assessed as it provides an objective measure to support the subjective patient reported outcomes of SGRQ and rescue medication use. The study is intended to provide additional evidence to support the use of UMEC/VI for the maintenance treatment of COPD Approximately 496 subjects will be randomized from approximately 62 centers in order to ensure 422 subjects complete 12 weeks of treatment. Eligible subjects will be randomized to UMEC/VI 62.5/25mcg or placebo in a 1:1 ratio. All treatments will be administered once-daily in the morning via a Dry Powder Inhaler (DPI).

There will be a total of 5 clinic visits. The total duration of study participation will be approximately 15 weeks. All subjects will be provided with albuterol/salbutamol to use as needed for the relief of COPD symptoms throughout the run-in and double-blind treatment periods.

研究概览

地位

完全的

条件

肺部疾病，慢性阻塞性

干预/治疗

研究类型

介入性

注册 (实际的)

498

阶段

第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

乌克兰
- - Kharkiv、乌克兰、61124
    - GSK Investigational Site
  - Kharkiv、乌克兰、61002
    - GSK Investigational Site
  - Kiev、乌克兰、03680
    - GSK Investigational Site
  - Kyiv、乌克兰、02232
    - GSK Investigational Site
  - Kyiv、乌克兰、01114
    - GSK Investigational Site
俄罗斯联邦
- - Ekaterinburg、俄罗斯联邦、620039
    - GSK Investigational Site
  - Moscow、俄罗斯联邦、117997
    - GSK Investigational Site
  - Novosibirsk、俄罗斯联邦、630099
    - GSK Investigational Site
  - Saint Petesburg、俄罗斯联邦、195030
    - GSK Investigational Site
  - Sestroretsk、俄罗斯联邦、197706
    - GSK Investigational Site
  - St. Petersburg、俄罗斯联邦、194356
    - GSK Investigational Site
  - St. Petersburg、俄罗斯联邦、198216
    - GSK Investigational Site
  - Stavropol、俄罗斯联邦、355017
    - GSK Investigational Site
  - Ulyanovsk、俄罗斯联邦、432063
    - GSK Investigational Site
  - Voronezh、俄罗斯联邦、394018
    - GSK Investigational Site
保加利亚
- - Dupnitza、保加利亚、2600
    - GSK Investigational Site
  - Gabrovo、保加利亚、5300
    - GSK Investigational Site
  - Kyustendil、保加利亚、2500
    - GSK Investigational Site
  - Montana、保加利亚
    - GSK Investigational Site
  - Sevlievo、保加利亚、5400
    - GSK Investigational Site
  - Sliven、保加利亚、8800
    - GSK Investigational Site
  - Sofia、保加利亚、1336
    - GSK Investigational Site
匈牙利
- - Balassagyarmat、匈牙利、2660
    - GSK Investigational Site
  - Budapest、匈牙利、1085
    - GSK Investigational Site
  - Budaörs、匈牙利、2040
    - GSK Investigational Site
  - Debrecen、匈牙利、4032
    - GSK Investigational Site
  - Gödöllő、匈牙利、2100
    - GSK Investigational Site
  - Nyíregyháza、匈牙利、4400
    - GSK Investigational Site
  - Szeged、匈牙利、6722
    - GSK Investigational Site
  - Szikszó、匈牙利、3800
    - GSK Investigational Site
德国
- - Berlin、德国、10717
    - GSK Investigational Site
  - Berlin、德国、10119
    - GSK Investigational Site
  - Berlin、德国、10629
    - GSK Investigational Site
  - Hamburg、德国、22143
    - GSK Investigational Site
- Hessen
  - Kassel、Hessen、德国、34121
    - GSK Investigational Site
- Niedersachsen
  - Weyhe-Leeste、Niedersachsen、德国、28844
    - GSK Investigational Site
- Schleswig-Holstein
  - Reinfeld、Schleswig-Holstein、德国、23858
    - GSK Investigational Site
罗马尼亚
- - Cluj-Napoca、罗马尼亚、400371
    - GSK Investigational Site
  - Codlea、罗马尼亚、505100
    - GSK Investigational Site
  - Craiova、罗马尼亚、200642
    - GSK Investigational Site
  - Deva、罗马尼亚、330084
    - GSK Investigational Site
  - Iasi、罗马尼亚、700115
    - GSK Investigational Site
  - Pitesti、罗马尼亚、110084
    - GSK Investigational Site
美国
- Arizona
  - Phoenix、Arizona、美国、85006
    - GSK Investigational Site
- California
  - Upland、California、美国、91786
    - GSK Investigational Site
- Florida
  - Clearwater、Florida、美国、33765-2616
    - GSK Investigational Site
- Missouri
  - Saint Charles、Missouri、美国、63301
    - GSK Investigational Site
- South Carolina
  - Anderson、South Carolina、美国、29621
    - GSK Investigational Site
  - Easley、South Carolina、美国、29640
    - GSK Investigational Site
  - Mount Pleasant、South Carolina、美国、29464
    - GSK Investigational Site
  - Rock Hill、South Carolina、美国、29732
    - GSK Investigational Site
  - Seneca、South Carolina、美国、29678
    - GSK Investigational Site
  - Union、South Carolina、美国、29379
    - GSK Investigational Site
- Texas
  - San Antonio、Texas、美国、78229
    - GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Type of subject: Outpatient.
Informed Consent: A signed and dated written informed consent prior to study participation.
Age: 40 years of age or older at Visit 1.
Gender: Male and female subjects are eligible to participate in the study.
A female subject is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile (For example [e.g.] age appropriate, >45 years, in the absence of hormone replacement therapy; or child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label, if appropriate, and the instructions of the physician for the duration of the study screening to follow-up contact): abstinence; oral contraceptive (either combined or progestogen alone); injectable progestogen; implants of levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label; male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study (this male is the sole partner for that subject); and double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society.
Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g. 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years both equal 10 pack-years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack-year history.
Severity of Disease: A pre and post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 and a post-albuterol/salbutamol FEV1 of <=70% of predicted normal values calculated using National Health and Nutrition Examination Survey (NHANES) III reference equations at Visit 1.
Dyspnea: A score of >=2 on the Modified Medical Research Council (mMRC) Dyspnea Scale at Visit 1.

Exclusion Criteria:

Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
Asthma: A current diagnosis of asthma.
Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to COPD should be excluded. Examples may include clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
Other Diseases/Abnormalities: Any subject who is considered unlikely to survive the duration of the study period or has any rapidly progressing disease or immediate life-threatening illness (e.g. cancer). In addition, any subject who has any condition (e.g. neurological condition) that is likely to affect respiratory function should not be included in the study.
Severe Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh class C) should be excluded unless, in the opinion of the investigator, the benefit is likely to outweigh the risk.
Unstable or life threatening cardiac disease: UMEC/VI should be used with caution in subjects with severe cardiovascular disease. In the opinion of the investigator, use should only be considered if the benefit is likely to outweigh the risk in conditions such as: myocardial infarction or unstable angina in the last 6 months; unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV heart failure.
Contraindications: Any history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, lactose/milk protein or magnesium stearate.
Antimuscarinic effects: Subjects with medical conditions such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction should only be included if, in the opinion of the study physician, the benefit outweighs the risk.
Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
Lung Resection: Lung volume reduction surgery within the 12 months prior to Visit 1.
12-Lead Electrocardiogram (ECG): Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. Subjects with the following abnormalities are excluded from participation in the study: Atrial fibrillation with rapid ventricular rate >120 beats per minute (bpm); Sustained or non-sustained ventricular tachycardia; Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted).
Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
Interactions: Concomitant administration with beta-blockers and strong Cytochrome P450 3A4 (CYP3A4) inhibitors is only permitted if, in the Investigator's opinion, the likely benefit outweighs the potential risk.
Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1: Depot corticosteroids (12 weeks), systemic, oral or parenteral corticosteroids (6 weeks), antibiotics (for lower respiratory tract infection) (6 weeks), Long acting Beta-Agonist (LABA)/ Inhaled Corticosteroid (ICS) combination products if LABA/ICS therapy is discontinued completely (30 days), LABA/ICS combination products only if discontinuing LABA/ICS therapy and switching to ICS monotherapy (48 hours for salmeterol or formoterol component and 14 days for vilanterol component), ICS (dose >1000 mcg/day of fluticasone propionate or equivalent) (30 days), Initiation or discontinuation of ICS use (30 days), Phosphodiesterase 4 (PDE4) Inhibitor (roflumilast) (14 days), Inhaled long acting beta2 agonists (48 hours for salmeterol, formoterol, 14 days for olodaterol, indacaterol), Long-acting muscarinic antagonists (tiotropium, aclidinium, glycopyrronium, umeclidinium) (7 days), LAMA/LABA combination products if LAMA/LABA therapy is discontinued completely (Apply whichever mono component has the longest washout), Theophyllines (48 hours), Oral beta2-agonists (Long-acting [48 hours], short-acting [12 hours]), Inhaled short acting beta2-agonists (4 hours), Inhaled short-acting anticholinergics (4 hours), Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products (4 hours), Any other investigational medication (30 days or within 5 drug half-lives [whichever is longer])
Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., <=12 hours per day) is not exclusionary.
Nebulised Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulised therapy.
Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a questionnaire.
Previous participation in DB2113373 study: Subjects who have previously been assigned a subject number (enrolled) in GlaxoSmithKline study DB2113373.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

主要用途：治疗
分配：随机化
介入模型：并行分配
屏蔽：双倍的

手臂数量

武器和干预

参与者组/臂	干预/治疗
实验性的：Umeclidinium/Vilanterol 62.5/25 mcg once daily The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)	药品：UMEC/VI Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
安慰剂比较：Placebo once daily The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI	药品：Placebo Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo

研究衡量的是什么？

主要结果指标

结果测量	措施说明	大体时间
Change From Baseline in Mean St.George's Respiratory Questionnaire (SGRQ) Total Score at Day 84 大体时间：Baseline and Day 84	The SGRQ is a disease-specific questionnaire, self-completed by participants(par), used to evaluate the effect of UMEC/VI on health-related quality of life as compared to placebo in par with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Analysis was performed using mixed model repeated measures with covariates of Baseline (scores recorded prior to dosing on Day 1) SGRQ total score, centre group, smoking status, Day, treatment(trt), Day by Baseline interaction and Day by trt interaction, where Day is nominal. Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.	Baseline and Day 84

次要结果测量

结果测量	措施说明	大体时间
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 84 大体时间：Baseline and Day 84	FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 28, 56 and 84. Baseline is defined as the assessment taken pre-dose on Treatment Day 1. Trough FEV1 is defined as the FEV1 value obtained 24 hours after the previous morning's dosing. Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions.	Baseline and Day 84
Change From Baseline (BL) in Mean Number of Puffs of Rescue Medication Per Day Used Over Weeks 1-12 大体时间：Week 1 amd Week 12	Albuterol/salbutamol(A/S) was used as rescue medication and was provided to participants to use on an as-needed basis for relief of COPD symptoms throughout treatment periods. The number of puffs of rescue medication (A/S) per day over the entire 12 week treatment period was recorded and analyzed. For rescue use, 'day' is referred as the period between one record of rescue use and the next. Total puffs of rescue for each day = number of salbutamol puffs + (2 x number of salbutamol nebules). Analysis performed using mixed model repeated measures with covariates of BL(mean number of total puffs over the duration from First Day; defined as Latest of [7 days before Visit 2 and day after Visit 1] to Last Day(defined as Day before Visit 2)), smoking status, centre group, four-week period, treatment and period by BL interaction. Change from BL used weeks 1-4, 5-8, and 9-12 as covariates in the model and the overall least squares mean change for weeks 1-12 is estimated.	Week 1 amd Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

GlaxoSmithKline

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年9月1日

初级完成 (实际的)

2015年3月1日

研究完成 (实际的)

2015年3月5日

研究注册日期

首次提交

2014年5月29日

首先提交符合 QC 标准的

2014年5月29日

首次发布 (估计)

2014年6月2日

研究记录更新

最后更新发布 (实际的)

2017年11月9日

上次提交的符合 QC 标准的更新

2017年10月9日

最后验证

2017年10月1日

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD

研究概览

地位

条件

干预/治疗

研究类型

注册 (实际的)

阶段

联系人和位置

学习地点

参与标准

资格标准

适合学习的年龄

接受健康志愿者

有资格学习的性别

描述

学习计划

研究是如何设计的？

设计细节

手臂数量

武器和干预

参与者组/臂

干预/治疗

研究衡量的是什么？

主要结果指标

结果测量

措施说明

大体时间

次要结果测量

结果测量

措施说明

大体时间

合作者和调查者

赞助

出版物和有用的链接

有用的网址

研究记录日期

研究主要日期

学习开始

初级完成 (实际的)

研究完成 (实际的)

研究注册日期

首次提交

首先提交符合 QC 标准的

首次发布 (估计)

研究记录更新

最后更新发布 (实际的)

上次提交的符合 QC 标准的更新

最后验证

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

IPD 计划说明

研究数据/文件